Results 41 to 50 of about 3,781 (191)
Rifampicin-resistant/multidrug-resistant (RR/MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis (TB) are serious public health problem in Kazakhstan.
Shynar M. Maretbayeva +10 more
doaj +1 more source
To address the sub-optimal treatment outcomes among patients with multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), the National TB Programme in Belarus started using new drugs such as bedaquiline and delamanid in 2015-16.
Vera Auchynka +9 more
doaj +1 more source
We present the clinical case of effective treatment of tuberculosis in a patient with disseminated pulmonary and extrapulmonary pre-extensive drug resistant tuberculosis, HIV-infection and other severe opportunistic and concomitant infections.
S. Yu. Degtyareva +2 more
doaj +1 more source
Delamanid is one of the key new drugs for the treatment of multidrug-resistant and, in particular, extensively drug-resistant tuberculosis. However, due to its relatively recent introduction into clinical practice, data on the frequencу of resistance ...
S. N. Andreevskaya +6 more
doaj +1 more source
MICs of pretomanid and delamanid against different mycobacterial strains.
MICs of pretomanid and delamanid against different mycobacterial strains.
Livnat Afriat-Jurnou (2057317) +17 more
core +1 more source
Introduction. Against the backdrop of multiple and widespread drug resistance of Mycobacterium tuberculosis (MDR-TB), there has been a significant decline in the effectiveness of treatment of tuberculosis (TB) patients in Ukraine and globally. Therefore,
M.I. Sakhelashvili +3 more
doaj +1 more source
Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva +23 more
wiley +1 more source
Flowchart of patients eligible for the comparative effectiveness of delamanid analysis in the endTB observational cohort.
Zaw Myint (6166169) +30 more
core +1 more source
ABSTRACT Tuberculosis remains a major public health threat globally, with drug‐resistant strains undermining treatment efficacy. We analyzed 126 Mycobacterium tuberculosis (M. tuberculosis) isolates with diverse drug resistance spectra and selected 35 for whole genome sequencing (WGS) using Illumina NextSeq, SMRT PacBio Onso and SMRT PacBio Revio ...
Unarine Matodzi +5 more
wiley +1 more source
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone ...
Pauline Howell +13 more
wiley +1 more source

